Dammarenediol II
Based on 1 Customer Validation
Dammarenediol II is a ginsenoside precursor. Dammarenediol II reduces the activity of O-GlcNAc transferase (OGT) and downregulates the global O-GlcNAcylation level. Dammarenediol II inhibits the phosphorylation of Akt, mTOR and GSK3β. Dammarenediol II inhibits human carboxylesterase activity, VEGF-induced ROS production, stress fiber formation and vascular endothelial cadherin disruption. Dammarenediol II promotes cell apoptosis (apoptosis), increases the levels of cleaved PARP1 and p53, and inhibits retinal microvascular leakage. Dammarenediol II can be used in studies related to liver cancer and diabetic retinopathy.
For research use only. We do not sell to patients.
- Purity: 99.81%
- CAS No.: 14351-29-2
- Formula: C30H52O2
- Molecular Weight:444.73
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero | IC50 |
7 μg/mL
Compound: 2, dammarenediol-II
|
Antiviral activity against HSV1 MacIntyre replication in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
Antiviral activity against HSV1 MacIntyre replication in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
|
[PMID: 2828553] |
| Vero | IC50 |
7 μg/mL
Compound: 2, dammarenediol-II
|
Antiviral activity against HSV2 MS replication infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
Antiviral activity against HSV2 MS replication infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
|
[PMID: 2828553] |
Dammarenediol II (40 μM; 24 h) reduces O-GlcNAc levels in HepG2, Huh7, SK-HEP1, SNU-182 and SNU-387 cells[1].
Dammarenediol II (0.01-2.0 μg/mL; 30 min pretreatment, 10 min VEGF incubation) dose-dependently inhibits VEGF-induced intracellular ROS production in human umbilical vein endothelial cells, with the maximum inhibitory effect observed at 1.0 μg/mL[2].
Dammarenediol II (1 μg/mL; 30 min, 1 h VEGF) inhibits VEGF-induced stress fiber formation in human umbilical vein endothelial cells[2].
Dammarenediol II (1 μg/mL; 30 min preincubation, 90 min VEGF treatment) inhibits VEGF-induced VE-cadherin disruption and maintains the integrity of adherens junctions in human umbilical vein endothelial cells[2].
Dammarenediol II (0-50 μM; 24 h) significantly reduces the viability of HepG2 cells at 50 μM[1].
Dammarenediol II (0-40 μM; 24 h) significantly downregulates the expression level of OGT in HepG2 cells[1].
Dammarenediol II (0-40 μM; 24 h) reduces the EC50 of Etoposide (HY-13629) for regulating caspase-3/7 activity from 17.69 μM to 4.86 μM in HepG2 cells, upregulates the expression levels of cleaved-PARP1 and p53 proteins, induces apoptosis in HepG2, Huh7, SK-HEP1, SNU-182 and SNU-387 cells, and synergistically enhances the anticancer activity of Etoposide[1].
Dammarenediol II (40 μM; 24 h) inhibits the phosphorylation levels of Akt, GSK3β and mTOR in HepG2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Huh7, SK-HEP1, SNU-182, SNU-387 human liver carcinoma cells
-
Concentration:40 μM
-
Incubation Time:24 h
-
Result:Reduced O-GlcNAc levels in all tested human liver carcinoma cell lines: Huh7, SK-HEP1, SNU-182, and SNU-387.
-
Cell Line:HepG2 cells
-
Concentration:0, 2.5, 5, 10, 20, 40, 50 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the viability of HepG2 cells at 50 μM
-
Cell Line:HepG2 cells
-
Concentration:0, 10, 20, 40 μM + 20 μM Etoposide
-
Incubation Time:24 h
-
Result:Significantly increased the proportion of TUNEL-positive cells in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (6-week-old male; diabetic via single intraperitoneal injection of streptozotocin)[2]
-
Dosage:2.5 μg
-
Administration:intravitreal; single injection
-
Result:Completely blocked marked FITC-dextran extravasation in diabetic mouse retinas.
Reduced average FITC-dextran fluorescence intensity in diabetic mouse retinas to levels comparable to control mice (intensity was ~2-fold higher in untreated diabetic mice than controls).
Chemical Information
-
CAS No. 14351-29-2
-
Appearance Solid
-
Molecular Weight 444.73
-
Formula C30H52O2
-
Color White to off-white
-
SMILES
C[C@@]1(CC[C@@]2([H])C3(C)C)[C@@](CC[C@@]4([H])[C@]1(CC[C@]4([H])[C@@](C)(O)CC/C=C(C)\C)C)([H])[C@]2(CC[C@@H]3O)C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 10 mg/mL (22.49 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lee J, et al. Dammarenediol II enhances etoposide-induced apoptosis by targeting O-GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer. Mol Oncol. Published online December 30, 2025. [Content Brief]
[2]. Kim SH, et al. Dammarenediol-II Prevents VEGF-Mediated Microvascular Permeability in Diabetic Mice. Phytother Res. 2015;29(12):1910-1916. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2486 mL | 11.2428 mL | 22.4856 mL | 56.2139 mL |
| 5 mM | 0.4497 mL | 2.2486 mL | 4.4971 mL | 11.2428 mL | |
| 10 mM | 0.2249 mL | 1.1243 mL | 2.2486 mL | 5.6214 mL | |
| 15 mM | 0.1499 mL | 0.7495 mL | 1.4990 mL | 3.7476 mL | |
| 20 mM | 0.1124 mL | 0.5621 mL | 1.1243 mL | 2.8107 mL |
Powered by Bioz